Navigation Links
Frost & Sullivan Lauds Aesku.Diagnostics For Providing an Overall Analysis Platform For a Wide Range of Autoimmune Complications
Date:3/3/2009

LONDON, March 3 /PRNewswire/ -- Based on its recent analysis of the autoimmune disease diagnostics markets, Frost & Sullivan recognizes Aesku.Diagnostics with the 2008 European Frost & Sullivan Product Line Strategy Award for its consistent approach towards product development. It has anticipated and catered to the needs in bio-marker identification, offered versatile immunoassay systems, extended research capabilities as well as delivered unprecedented sensitivity and exceptional performance.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

In just eight years of its existence, Aesku.Diagnostics has acquired several antigen and therapy patents and has become a recognised name in the autoimmune diagnostics market in more than 80 countries. It has earned a solid reputation in the market for launching over 140 different products, catering to autoimmune diagnostics and laying equal emphasis on all the major disease sectors under the autoimmune disease diagnostic space.

"Its products fall under two major brands namely, AESKULISA(R) {enzyme-linked immunosorbent assays (ELISA) kits} and AESKUSLIDES(R) (immunofluorescence slide panels)," says Frost & Sullivan Suraj Ramanathan. "The AESKU tests are developed based on human recombinant antigens or native antigens (conformational epitopes) depending on the optimal clinical correlation."

ELISA kits are more popular for autoimmune diagnosis; the company provides more than 100 CE marked kits incorporating human recombinant antigens synthesized in-house to assure maximum sensitivity and specificity. The kits can be used for diagnosing rheumatology, thrombosis, gastroenterology, vasculitis, thyroid, diabetes, hepatology and other rare autoimmune complications. While its 30-30-30 test format can be used with most commercially available automated test platforms, its special in-house plate coating and production facility offers a shelf life of up to 24 months with a production capacity of nearly 500 plates per hour.

The AESKUSLIDES(R) brand encompasses a broad portfolio of immunofluorescence slides. All these slides are vacuum-sealed for longer shelf life as well as stability, and use a highly hydrophobic Teflon mask to avoid sample cross contamination.

Such innovations point to a strong focus on research. Aesku.Diagnostics is looking to centralise its research and production to provide a universal protocol compatible with both automated and manual handling of assays. This development methodology, known as the 'ONE' Aesku concept, includes one working protocol, one pre-dilution ratio, one buffer system, one reagent system, one calibration range, one cut-off and one assay platform for all available Aesku tests.

"The 'ONE' clearly improves the lab throughput and reduces the diagnosis time," notes Suraj Ramanathan. "Furthermore, the company has always adhered to providing customers with uninterrupted services and implementing novel strategies such as 'second opinion lab service', which aid customers with queries regarding sample diagnosis on a complementary basis."

Aesku.Diagnostics has also noted the necessity of automation in the autoimmunity lab, considering a tender is incomplete if the manufacturer/distributor does not offer automation of the tests. To address this need, it has developed HELMED(R), an automatic flexible processor capable of running and managing routine tests for autoimmunity and infectious serology within the laboratory.

The HELMED(R) project, together with the already implemented Aesku 'ONE; concept (the same reagent system and protocol being shared by the complete reagent panel), will give the company the tools and arguments to consolidate sales in mature markets," observes Ramanathan. "It will also increase market shares in the developing markets and have full control of the automation key, so important for the future of the business."

Each year, Frost & Sullivan presents this award to the company that has demonstrated the most insight into customer needs and product demands. The recipient company should have optimized its product line by leveraging products with the various price, performance, and feature points required by the market.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

ABOUT AESKU.DIAGNOSTICS

Aesku.Diagnostics, based in Wendelsheim, Germany, is a research-focused supplier of innovative and efficient products and services for the early detection, diagnosis and prognosis of autoimmune diseases. In only nine years since its foundation Aesku has become a recognized name in the autoimmune diagnostics market for launching over 140 different products clearly improving the lab throughput together with uninterrupted services in more than 80 countries worldwide. With Aesku.Systems (Lab automation) and Aesku.Therapy (Autoimmune Therapies) the company diversifies its portfolio consistently to meet upcoming needs in the autoimmune diseases sector. For more information about the Aesku group please visit www.aesku.com.

    Contact:
    Hugo Ribeiro, International Sales Manager AESKU.DIAGNOSTICS,
    ribeiro@aesku.com, P: 0049 (0) 6734.9627.0, Fax: 0049 (0) 6734.9627.27

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

    Contact:
    Ciara Jamie Connolly | Senior Events & Promotions Executive, EMEA, Best
    Practices, Frost & Sullivan, ciara.connolly@frost.com, P: 0044 (0)
    207.915.7868, F: 0044 (0) 207.730.3343, www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System
2. Frost & Sullivan Says, Rising Awareness Boosts High Acuity Areas Monitoring Systems Market in Eastern Europe
3. Frost & Sullivan Awards to Celebrate Healthcare Excellence
4. Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan
5. Frost & Sullivan: The Brazilian Municipal Water and Wastewater Treatment Market Set to Double Within the Next Seven Years
6. Frost & Sullivan: Novel Diagnostics Methods Driving the European Cancer IVD Market Towards Early Detection and Prevention
7. Frost & Sullivan Recognizes WCC for Its Unique Multimodal Platform
8. Frost & Sullivan Recognizes Horphags Pioneering R&D Efforts in Health Ingredients
9. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
10. Frost & Sullivan Recognizes Strategic Healthcare Programs for Best Practices in Focused Innovation
11. Frost & Sullivan Says, Innovative Therapies Needed to Deal With the Rapid Spread of Cancer in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: